ArticleCancer cell2023
IL-5-producing CD4
Open access · hybridAbstract read
In one paragraph
Article in Cancer cell, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 150 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
150citing papers in PubMed, 2 pooled it
15.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
150 citing papers in PubMed, 2 syntheses or guidelines pooled it, 195 citations in OpenAlex.
- Risk factors for checkpoint inhibitor pneumonitis in lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies.Molecular cancer · 2024Pooled it
- Anti-PD-1 plus nab-paclitaxel and bevacizumab for second-line treatment of cancer of unknown primary (Fudan CUP-002): a phase II trial.Nature communications · 2026Trial
- Temporal and spatial composition of the tumor microenvironment predicts response to immune checkpoint inhibition in metastatic TNBC.Nature cancer · 2026Trial
- CfDNA-based copy-number dynamics during anti-PD1 treatment in metastatic triple negative breast cancer.Cell reports. Medicine · 2025Trial
- Perioperative tislelizumab plus chemotherapy for locally advanced gastroesophageal junction adenocarcinoma (NEOSUMMIT-03): a prospective, nonrandomized, open-label, phase 2 trial.Signal transduction and targeted therapy · 2025Trial
- Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial.Nature communications · 2024Trial
- Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.Nature medicine · 2024Trial
- Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.Nature medicine · 2024Trial
- PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.Nature cancer · 2023Trial
- GELATO - a clinical trial specific for patients with lobular breast cancer.Nature cancer · 2023Trial
- The peripheral immune landscape of human breast cancer.Oncoimmunology · 2026Review
- Radiation-induced CD200Cellular & molecular immunology · 2026Article
- Skin Rash Management Based on Early Elevation in the Eosinophil Proportion Within 3 Months of Initiating Apalutamide for Prostate Cancer.Cancer reports (Hoboken, N.J.) · 2026Article
- Article
- Eosinophil diversity and function: emerging insights into subtypes and therapeutic targets.Cell death discovery · 2026Review
- Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune-Related Adverse Events in Patients With Bladder Cancer.Cancer medicine · 2026Observational
- Histidine to glutamine substitutants, a regulated process that impacts cell survival and suggests histidine shortage in cancer.Cell death discovery · 2026Article
- Advancements in Immune Checkpoint-Based Immunotherapy for Triple-Negative Breast Cancer.Current issues in molecular biology · 2026Review
- Rapidly progressive squamous lung cancer with peripheral blood eosinophilia in a 25-year-old woman: A case report.Oncology letters · 2026Article
90 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
29 authors at 3 institutions in 2 countries.
Olga S BlombergDivision of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands; Department of Immunology, Leiden University Medical Centre, Leiden, the Netherlands.
Lorenzo SpagnuoloDivision of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
Hannah GarnerDivision of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
Leonie VoorwerkDivision of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Olga I IsaevaDivision of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Ewald van DykDivision of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Noor BakkerDivision of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
Myriam ChalabiDivision of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Chris KlaverDivision of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Maxime DuijstDivision of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Kelly KerstenDivision of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Marieke BrüggemannDivision of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Dorien PastoorsDivision of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
Cheei-Sing HauDivision of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
Kim VrijlandDivision of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
Elisabeth A M RaevenDivision of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
Daphne KaldenbachDivision of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
Kevin KosDivision of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands; Department of Immunology, Leiden University Medical Centre, Leiden, the Netherlands.
Inna S AfoninaVIB-UGent Center for Inflammation Research, Ghent University, Ghent, Belgium; Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.
Paulien KapteinDivision of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Louisa HoesOncode Institute, Utrecht, the Netherlands; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Willemijn S M E TheelenDepartment of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Paul BaasDepartment of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Emile E VoestOncode Institute, Utrecht, the Netherlands; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Rudi BeyaertVIB-UGent Center for Inflammation Research, Ghent University, Ghent, Belgium; Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.
Daniela S ThommenDivision of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Lodewyk F A WesselsOncode Institute, Utrecht, the Netherlands; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Karin E de VisserDivision of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands; Department of Immunology, Leiden University Medical Centre, Leiden, the Netherlands. Electronic address: k.d.visser@nki.nl.
Marleen KokDivision of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. Electronic address: m.kok@nki.nl.
Oncode Institute · NLThe Netherlands Cancer Institute · NLGhent University · BE
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint blockade (ICB) has heralded a new era in cancer therapy. Research into the mechanisms underlying response to ICB has predominantly focused on T cells; however, effective immune responses require tightly regulated crosstalk between innate and adaptive immune cells. Here, we combine unbiased analysis of blood and tumors from metastatic breast cancer patients treated with ICB with mechanistic studies in mouse models of breast cancer. We observe an increase in systemic and intratumoral eosinophils in patients and mice responding to ICB treatment. Mechanistically, ICB increased IL-5 production by CD4
Indexed as
Immune Checkpoint InhibitorsNeoplasmsAnimalsAntigen PresentationCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesEosinophilsInterleukin-33Interleukin-5MiceImmune Checkpoint InhibitorsInterleukin-33Interleukin-5breast cancerCD4(+) T cellseosinophilsIL-33IL-5immune checkpoint blockademyeloid cells
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.